Effects of small interfering RNA targeting sphingosine kinase-1 gene on the animal model of Alzheimer’s disease

Abstract

Alzheimer’s disease (AD) is an age-related, progressive neurodegenerative disorder that occurs gradually and results in memory, behavior, and personality changes. Abnormal sphingolipid metabolism was reported in AD previously. This study aimed to investigate whether sphK1 could exacerbate the accumulation of amyloid protein (Aβ) and sharpen the learning and memory ability of the animal model of AD using siRNA interference. An adenovirus vector expressing small interfering RNA (siRNA) against the sphK1 gene (sphK1-siRNA) was designed, and the effects of sphK1-siRNA on the APP/PS1 mouse four weeks after treatment with sphK1-siRNA hippocampal injection were examined. SphK1 protein expression was confirmed by using Western blotting and ceramide content coupled with S1P secretion was evaluated by enzyme-linked immunosorbent assay (ELISA). Aβ load was detected by immunohistochemical staining and ELISA. Morris water maze was adopted to test the learning and memory ability of the APP/PS1 mice. A significant difference in the expression of sphK1 protein and mRNA was observed between the siRNA group and the control group. Aβ load in transfected mice was accelerated in vivo, with significant aggravation of the learning and memory ability. The sphK1 gene modulation in the Aβ load and the learning and memory ability in the animal model of AD may be important for the treatment of AD.

Keywords

Alzheimer’s disease / sphingolipid metabolism / sphK1 gene / small interfering RNA / mice

References

[1] SelkoeD. The deposition of amyloid proteins in the aging mammalian brain: implications for Alzheimer’s disease. Ann Med, 1989, 21(2): 73-76

[2] HeX, HuangY, LiB, et al.. Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiol Aging, 2010, 31(3): 398-408

[3] WalshDM, SelkoeDJ. Aβ oligomers-a decade of discovery. J Neurochem, 2007, 101(5): 1172-1184

[4] KirkitadzeMD, BitanG, TeplowDB. Paradigm shifts in Alzheimer’s disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res, 2002, 69(5): 567-577

[5] ShankarGM, LiS, MehtaTH, et al.. Amyloid-β protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med, 2008, 14(8): 837-842

[6] NäslundJ, HaroutunianV, MohsR, et al.. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA, 2000, 283(12): 1571-1577

[7] HannunYA, ObeidLM. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem, 2002, 277(29): 25847-25850

[8] SpiegelS, MilstienS. Sphingosine-1-phosphate: an enigmatic signalling. Nat Rev Mol Cell Biol, 2003, 4(5): 397-407

[9] BryanL, KordulaT, SpiegelS, et al.. Regulation and functions of sphingosine kinases in the brain. Biochim Biophys Acta, 2008, 1781(9): 459-466

[10] Gomez-BrouchetA, PchejetskiD, BrizuelaL, et al.. Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide. Mol Pharmacol, 2007, 72(2): 341-349

[11] Van BrocklynJR, JacksonCA, PearlDK, et al.. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol, 2005, 64(8): 695-705

[12] LiuH, SugiuraM, NavaVE, et al.. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem, 2000, 275(26): 19513-19520

[13] SpiegelS, MilstienS. Functions of the multifaceted family of sphingosine kinases and some close relatives. J Biol Chem, 2007, 282(4): 2125-2129

[14] AnelliV, GaultCR, ChengAB, et al.. Sphingosine kinase 1 is upregulated during hypoxia in U87MG glioma cells: role of hypoxia-inducible factors 1 and 2. J Biol Chem, 2008, 283(6): 3365-3375

[15] ShinpoK, KikuchiS, MoriwakaF, et al.. Protective effects of the TNF-ceramide pathway against glutamate neurotoxicity on cultured mesencephalic neurons. Brain Res, 1999, 819(1–2): 170-173

[16] KajimotoT, OkadaT, YuH, et al.. Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons. Mol Cell Biol, 2007, 27(9): 3429-3440

[17] RobbinsPD, GhivizzaniSC. Viral vectors for gene therapy. Pharmacol Ther, 1998, 80(1): 35-47

[18] ChangKA, SuhYH. Pathophysiological roles of amyloidogenic carboxy-terminal fragments of the β-amyloid precursor protein in Alzheimer’s disease. J Pharmacol Sci, 2005, 97(4): 461-471

[19] ZhangYH, FehrenbacherJC, VaskoMR, et al.. Sphingosine-1-phosphate via activation of a G-protein-coupled receptor (s) enhances the excitability of rat sensory neurons. J Neurophysiol, 2006, 96(3): 1042-1052

[20] PatilS, MelroseJ, ChanC. Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons. Eur J Neurosci, 2007, 26(8): 2131-2141

[21] PuglielliL, EllisBC, SaundersAJ, et al.. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem, 2003, 278(22): 19777-19783

[22] TamboliIY, PragerK, BarthE, et al.. Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J Biol Chem, 2005, 280(30): 28110-28117

[23] GrimmMO, GrimmHS, PätzoldAJ, et al.. Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin. Nat Cell Biol, 2005, 7(11): 1118-1123

[24] PalopJJ, MuckeL. Amyloid-beta-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks. Nat Neurosci, 2010, 13(7): 812-818

[25] HaugheyNJ, BandaruVV, BaeM, et al.. Roles for dysfunctional sphingolipid metabolism in Alzheimer’s disease neuropathogenesis. Biochim Biophys Acta, 2010, 1801(8): 878-886

[26] YuN, Lariosa-WillinghamKD, LinFF, et al.. Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia, 2004, 45(1): 17-27